Our Take
Daraxonrasib's 60% mortality reduction in pancreatic cancer is real and substantial, but the framing as a paradigm shift glosses over the fact that median survival data and long-term durability remain absent from publicly available trial results.
Why it matters
Pancreatic cancer has one of the worst prognoses in oncology; any material survival gain reshapes treatment options for a population with few alternatives. ASCO 2026 also highlighted progress across lung, blood, and prostate cancers, signaling a shift toward earlier intervention and multi-target approaches in solid tumors.
Do this week
Oncology medical directors: request the full OrigAMI-4 and PROTEUS New England Journal of Medicine publications before updating pancreatic and prostate cancer protocols, since response rates and durability data are critical to sequencing decisions.
Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60%
Revolution Medicine's daraxonrasib, a once-daily oral RAS inhibitor, met all primary and secondary endpoints in a phase 3 trial of 500 patients with pancreatic ductal adenocarcinoma. The drug reduced death risk by 60% (company-reported) compared to chemotherapy. In patients with a RAS G12 mutation, the objective response rate was 33.2% on daraxonrasib versus 11.8% with chemotherapy. In the intent-to-treat population, 31.6% responded to daraxonrasib versus 11.2% with chemotherapy.
Daraxonrasib works by inhibiting the KRAS protein, which when mutated drives tumor growth. Brian Wolpin, the trial's principal investigator, called the results a "major milestone," noting that second-line chemotherapy offers "modest benefits" and new treatments delivering durable tumor control have been "urgently needed."
Pancreatic Cancer Lacks Effective Post-Chemotherapy Options
Pancreatic ductal adenocarcinoma is one of oncology's hardest-to-treat malignancies. Most patients who fail initial chemotherapy have few approved alternatives. A 60% reduction in death risk represents a measurable advance over the current standard of care, though median overall survival and long-term durability data were not disclosed in the ASCO presentation.
ASCO 2026 also surfaced meaningful progress across other cancer types. Johnson & Johnson's Rybrevant Faspro achieved a 42% overall response rate in head and neck cancers that had progressed on both immunotherapy and chemotherapy, with a median overall survival of 12.5 months. In prostate cancer, the PROTEUS study showed that neoadjuvant treatment reduced the risk of metastasis or death by 20%, and patients were nine times more likely to have minimal cancer remaining at surgery. AbbVie's ADC ABBV-706 in small cell lung cancer showed an 82% overall response rate at 1.8 mg/kg in phase 3 studies.
Response Rates Alone Do Not Predict Real-World Benefit
Oncologists should distinguish between response rates and durable survival gains. Daraxonrasib's 33% response rate in RAS G12-mutant pancreatic cancer is noteworthy, but the absence of disclosed median overall survival and progression-free survival figures limits the ability to benchmark durability against existing standards or predict which patients will derive lasting benefit.
Similarly, Rybrevant Faspro's 42% response rate in heavily pretreated head and neck cancer does not yet establish whether the subcutaneous delivery format—a practical advantage over intravenous therapy—translates to improved adherence or outcomes in practice. The PROTEUS prostate cancer data, published simultaneously in the New England Journal of Medicine, offers clearer long-term signal: a 20% reduction in metastasis or death and a six-year delay in the need for additional treatment warrant close review of the full manuscript before protocol adoption.
Antibody-drug conjugates and T-cell engagers continue to mature. AbbVie's etentamig, a T-cell engager, achieved up to 64% overall response rates in relapsed/refractory multiple myeloma, including in CAR-T-experienced patients. Storm Therapeutics' STC-15, a METTL3 inhibitor targeting sarcoma stem cells, showed tolerability in phase 1 and is moving to phase 2 in selected sarcomas. Syndax's revumenib, a menin inhibitor approved in 2024 for relapsed acute leukemia, showed 90% two-year overall survival as post-transplant maintenance in a 24-patient study, though the small sample size warrants larger confirmation.